HER3 expression in primary colorectal cancer including corresponding metastases in lymph node and liver

Figures & data

Table I. Patients and primary CRC tumour characteristics and HER3 expression in primary tumour.

	Number of patients	HER3 expression in primary tumour low vs. high	p
Total	107	21 (20%) vs. 86 (80%)
Gender
Male	64 (60%)	11 (17%) vs. 53 (83%)	p = 0.4
Female	43 (40%)	10 (23%) vs. 33 (77%)
Age
< 64 years	55 (51%)	10 (18%) vs. 45 (82%)	p = 0.7
≥ 64 years	52 (49%)	11 (21%) vs. 41 (79%)
Stage
II	17 (16%)	4 (24%) vs. 13 (76%)	p = 0.9
III	30 (28%)	6 (20%) vs. 24 (80%)
IV	60 (56%)	11 (18%) vs. 49 (82%)
Tumour site
Colon	55 (51%)	9 (16%) vs. 46 (84%)	p = 0.4
Rectum	52 (49%)	12 (23%) vs. 40 (77%)
Grade (differentiation)
Poor	18 (17%)	4 (22%) vs. 14 (78%)	p = 0.9
Moderately/Well	89 (83%)	16 (19%) vs. 69 (81%)
Liver metastases
Synchronous (≤ 6 months)	61 (57%)*	12 (20%) vs. 49 (80%)
Metachronous (> 6 months)	46 (43%)	9 (20%) vs. 37 (80%)	p = 1.0
Treatment
Surgery only	51 (48%)	10 (20%) vs. 41 (80%)
Chemotherapy or Radiation or Chemotherapy + Radiation	56 (52%)	11 (20%) vs. 45 (80%)	p = 1.0
Intravascular invasion
No intravascular invasion	29/59 (49%)	2 (7%) vs. 27 (93%)
(48/107 missing data)	30/59 (51%)	6 (20%) vs. 24 (80%)	p = 0.1
Perineural invasion
No perineural invasion	15/48 (31%)	2 (13%) vs. 13 (87%)
(59/107 missing data)	33/48 (69%)	5 (15%) vs. 28 (85%)	p = 0.9
Nodes analysed
< 12	40 (37%)	8 (20%) vs. 32 (80%)
≥ 12	67 (63%)	13 (19%) vs. 54 (81%)	p = 0.9

٭One patient developed liver metastatic disease within 6 months from primary diagnosis of CRC and was therefore not classified as Stage IV initially.

Figure 1. Immunohistochemically detection of HER3 expression CRC primary tumour, grade 0–3 and HER3 expression, grade 3, in lymph node and liver CRC metastasis (magnification × 40).

Figure 2. Overall survival in months from primary CRC surgery related to high or low HER3 expression.